THE biosimilar version of the breast cancer drug trastuzumab was approved by the United States Food and Drug Administration (FDA) in December. Not long after, neighbouring Thailand also registered the drug.
But the Malaysian authorities are dragging their feet in registering the the drug, which could bring some hope to patients who wanted the targeted drug therapy.
Already a subscriber? Log in.
Limited time offer:
Just RM5 per month.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!